Author:
Ma Cynthia X.,Reinert Tomás,Chmielewska Izabela,Ellis Matthew J.
Publisher
Springer Science and Business Media LLC
Subject
General Earth and Planetary Sciences,General Environmental Science
Reference181 articles.
1. Beatson, G. T. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet 33, 108–121 (1983). This paper is the starting place for any discussion of endocrine therapy and reminds us how instructive case reports can be: the genomic analysis of extreme responders to targeted therapy is a modern iteration of this theme.
2. Lin, N. U. & Winer, E. P. Advances in adjuvant endocrine therapy for postmenopausal women. J. Clin. Oncol. 26, 798–805 (2008).
3. Pagani, O. et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. New Engl. J. Med. 371, 107–118 (2014). This is a well-powered study showing a benefit for the AI exemestane versus tamoxifen in combination with ovarian suppression. Further follow-up will be required to demonstrate the full magnitude of the advantage of AIs in this setting.
4. Di Leo, A. et al. Final overall survival: fulvestrant 500 mg versus 250 mg in the randomized CONFIRM trial. J. Natl Cancer Inst. 106, djt337 (2014).
5. Robertson, J. F. R. et al. Fulvestrant 500 mg versus anastrozole as first-line treatment for advanced breast cancer: overall survival from the phase II 'first' study. Abstracts from the 37th Annual SABCS S6–04 (2014).
Cited by
330 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献